Related Experiment Video
Updated: May 30, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Effectiveness of Adjuvant Chemo- and Radiotherapy in Thymic Carcinoma Stage II: A Systematic Review and Meta-Analysis
Ahmad Nazzal1, Josef Yayan1, Christian Biancosino2
1Department of Internal Medicine, Division of Pulmonary, Allergy and Sleep Medicine, HELIOS Clinic Wuppertal, Witten/Herdecke University, Witten, Germany.
Background:
Thymic carcinoma is a rare tumor arising from the epithelial thymic tissue, yet among mediastinal tumors, it is the most common malignant entity. Thymic carcinoma often causes no symptoms and is incidentally discovered. Adjuvant radiotherapy is recommended, particularly in cases of incomplete resection and for stages III and IV, based on current guidelines and existing literature. In stage II (Masaoka-Koga system), the role of chemotherapy remains controversial, particularly in cases of incomplete resection. Therefore, this study aims to assess the effectiveness of adjuvant chemotherapy compared to adjuvant radiotherapy in the treatment of stage II (Masaoka-Koga system) thymic carcinoma after surgery.
Methods:
A comprehensive literature search was conducted in the Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and MEDLINE/PubMed databases for relevant studies published through April 30th, 2023.
Results:
The review identified a total of 101 studies in the Embase, Cochrane Library, and MEDLINE/PubMed databases. Of these, only eight retrospective studies met the inclusion criteria and were included in the meta-analysis. These eight studies encompassed a total of 323 patients with stage II (Masaoka-Koga system) thymic carcinoma, with an average patient age of 53.8 ± 5.0 years. There was no significant difference in the number of R0 resections between patients receiving adjuvant chemotherapy and those receiving adjuvant radiotherapy (P = 0.82). Patients who received adjuvant radiotherapy had a higher rate of recurrence, but this difference was not statistically significant (P = 0.93). The meta-analysis synthesized five-year overall survival data, with a combined hazard ratio (HR) of 0.881 (95% CI: 0.463 to 1.299), indicating no statistically significant difference between the treatment groups.
Conclusions:
Although the results were not statistically significant, the findings suggest that adjuvant chemotherapy might be associated with a more favorable outcome for patients with stage II (Masaoka-Koga system) thymic carcinoma compared to adjuvant radiotherapy.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Related Concept Videos
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...